Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
90 Cards in this Set
- Front
- Back
lymph node paracortex houses
|
T cells
|
|
lymph node medullary sinuses house
|
macrophages
|
|
lymph node medullary cords house...
|
lymphocytes and plasma cells
|
|
positive selection of T cells occurs in the...
|
cortex of thymus
|
|
negative selection of T cells occurs in the...
|
corticomedullary junction of the thymus
|
|
lymph node drainage of rectum above pectinate line
|
internal iliac nodes
|
|
lymphatic drainage of rectum below pectinate line (aka the anus)
|
superficial inguinal nodes
|
|
lymphatic drainage of scrotum
|
superficial inguinal nodes
|
|
lymphatic drainage of superficial thigh
|
superficial inguinal nodes
|
|
lymphatic drainage of lateral side of dorsum of foot
|
popliteal nodes
|
|
HLA A3
|
hemochromatosis
|
|
HLA B27
|
psoriasis, ankylosing spondylitis, IBD, reactive arthritis (Reiter's)
|
|
HLA B8
|
Graves' disease
|
|
HLA DR2
|
Goodpasture's syndrome, MS, SLE, hay fever
|
|
HLA DR3
|
T1DM
|
|
HLA DR4
|
T1DM, RA
|
|
HLA DR5
|
Hashimoto's thyroiditis, pernicious anemia
|
|
HLA DR7
|
steroid-responsive nephrotic syndrome
|
|
2 signal hypothesis - APC --> CD4+ T cell
|
1) MHC I --> TCR/CD4
2) B7 --> CD28 |
|
2 signal hypothesis - virus-infected cell --> CD8+ T cell
|
1) MHC I --> TCR/CD8
2) IL-2 from Th1 cell |
|
2 signal hypothesis - Th2 cell --> B cell
|
1) CD40L --> CD40
2) IL-4, 5, 6 (activates B cell, stimulates class-switching) |
|
stimulus for classical complement pathway
|
ag/ab complexes
|
|
stimulus for lectin complement pathway
|
mannose residues on microbial surface
|
|
stimulus for alternative complement pathway
|
spontaneous
|
|
convergence point of 3 complement pathways
|
C3 --> C3b and C3a
|
|
neutrophil chemotactants
|
C5a, IL-8, LTB4, kallekrein
|
|
complement factors causing anaphylaxis
|
C3a, C5a
|
|
opsonizing complement factor
|
C3b
|
|
deficiency causing hereditary angioedema
|
C1 esterase inhibitor deficiency
|
|
IL-X: a pyrogen that increases adhesion molecules on the endothelium and recruits leukocytes; secreted by macrophages
|
IL-1
|
|
IL-X: a pyrogen that increases acute phase proteins, secreted by macrophages and Th
|
IL-6
|
|
IL-X: the major chemotactic factor for neutrophils, secreted by macrophages
|
IL-8
|
|
IL-X: induces T cell differentiation to Th1 and activates NK cells; secreted by macrophages and B cells
|
IL-12
|
|
a major mediator of septic shock secreted by macrophages
|
TNF-alpha
|
|
IL-X: supports growth, differentiation of bone marrow HSCs, secreted by all T cells
|
IL-3
|
|
IL-X: stimulates growth of helper and cytotoxic T cells, secreted by Th1
|
IL-2
|
|
class of cytokines active against viruses
|
interferons
|
|
receptor for EBV
|
CD21
|
|
marker for macrophages
|
CD14
|
|
markers for NK cells
|
CD16, CD56
|
|
type _ hypersensitivity: hemolytic anemia, pernicious anemia, ITP, acute hemolytic transfusion rxn
|
Type 2
|
|
type _ hypersensitivity: rheumatic fever, Goodpasture's syndrome
|
type 2
|
|
type _ hypersensitivity: bullous pemphigoid, pemphigus vulgaris
|
type 2
|
|
type _ hypersensitivity: Graves disease, myasthenia gravis, rheumatic fever
|
type 2
|
|
type _ hypersensitivity: SLE, RA, polyarteritis nodosum, poststrep glomerulonephritis, hypersensitivity pneumonitis
|
type 3
|
|
type _ hypersensitivity: serum sickness, Arthus rxn
|
type 3
|
|
type _ hypersensitivity: T1DM
|
type 4
|
|
type _ hypersensitivity: MS, Guillain-Barre
|
type 4
|
|
type _ hypersensitivity: Hashimoto's
|
type 4
|
|
type _ hypersensitivity: GVHD
|
type 4
|
|
type _ sensitivity: contact dermatitis, as from poison ivy or nickel
|
type 4
|
|
anti-dsDNA, anti-Smith antibodies
|
SLE, specific
|
|
anti-histone antibodies
|
drug-induced lupus
|
|
anti-IgG antibodies
|
RA (this is rheumatoid factor!)
|
|
anti-centromere antibodies
|
systemic sclerosis, limited (CREST)
|
|
anti-Scl-70/anti-DNA topoisomerase I antibodies
|
systemic sclerosis, diffuse
|
|
anti-mitochondrial antibodies
|
primary biliary cirrhosis
|
|
anti-endomyosial antibodies
|
Celiac disease
|
|
anti-desmoglein antibodies
|
pemphigus vulgaris
|
|
anti-hemidesmosome antibodies
|
bullous pemphigoid
|
|
anti-microsomal antibodies
|
Hashimoto's
|
|
anti-Jo-1 antibodies
|
polymyositis, dermatomyositis
|
|
anti-SS-A/Ro, anti-SS-B/La antibodies
|
Sjogren's syndrome
|
|
anti-U1 ribonucleoprotein antibodies
|
mixed connective tissue disease
|
|
anti-smooth muscle antibodies
|
autoimmune hepatitis
|
|
anti-glutamate decarboxylase antibodies
|
T1DM
|
|
c-ANCA
|
Wegener's granulomatosis
|
|
defect in BTK gene
|
Bruton's agammaglobulinemia
|
|
defect in CD40L gene
|
hyper-IgM syndrome
|
|
coarse facies, cold Staph abscesses, retained primary teeth, hyper IgE, eczema
|
hyper-IgE (Job's) syndrome
|
|
IL-2 R defect
|
SCID
|
|
ATM gene defect
|
ataxia-telangectasia (has IgA deficiency)
|
|
defect in LFA-1 integrin (CD18)
|
leukocyte adhesion deficiency type 1
|
|
defect in LYST gene
|
Chediak-Higashi syndrome (mt dysfunction-->phagocyte dysfxn)
|
|
negative nitroblue tetrazolium dye reduction test
|
CGD
|
|
cyclosporine
|
calcineurin inhibitor
|
|
tacrolimus (FK506)
|
calcineurin inhibitor
|
|
sirolimus (rapamycin)
|
mTOR inhibitor
|
|
azathioprine
|
precursor of 6-MP (antimetabolite)
|
|
aldesleukin
|
recombinant IL-2
|
|
filgrastim, sargramostim
|
GC-SF, GMC-SF
|
|
therapy for CGD
|
IFN-gamma
|
|
oprelvekin
|
recombinant IL-11, stimulates thrombocyte production
|
|
muromonoab
|
anti-CD3
|
|
daclizumab
|
anti IL-2 receptor
|
|
infliximab, adalimumab
|
anti-TNF alpha
|
|
abciximab
|
anti-glycoprotein IIb/IIIa
|
|
trastuzumab
|
anti-erbB2 (HER2+ breast CA)
|
|
rituximab
|
anti-CD20 (especially useful for follicular lymphoma)
|
|
omalizumab
|
anti-IgE (severe asthma)
|